Esperion Therapeutics, Inc. (NASDAQ:ESPR) is scheduled to release its earnings data before the market opens on Wednesday, November 1st. Analysts expect Esperion Therapeutics to post earnings of ($1.79) per share for the quarter.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.25). During the same quarter in the prior year, the business earned ($0.62) earnings per share. On average, analysts expect Esperion Therapeutics to post $-7.12 EPS for the current fiscal year and $-5.96 EPS for the next fiscal year.

Esperion Therapeutics, Inc. (NASDAQ ESPR) opened at 44.05 on Wednesday. The firm’s market cap is $995.22 million. The stock has a 50 day moving average price of $51.17 and a 200 day moving average price of $43.93. Esperion Therapeutics, Inc. has a 52-week low of $9.40 and a 52-week high of $57.40.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/25/esperion-therapeutics-inc-espr-scheduled-to-post-earnings-on-wednesday.html.

A number of research analysts recently weighed in on ESPR shares. UBS AG reiterated a “buy” rating and issued a $57.00 price objective (up from $52.00) on shares of Esperion Therapeutics in a research note on Tuesday, June 27th. Jefferies Group LLC started coverage on shares of Esperion Therapeutics in a research note on Monday, July 10th. They issued a “hold” rating and a $55.00 price objective for the company. BidaskClub lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 4th. Needham & Company LLC lifted their price objective on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a research note on Tuesday, August 8th. Finally, Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $58.92.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.